Results 81 to 90 of about 18,827 (200)
Molecular Oncology, Volume 20, Issue 9, Page 2188-2202, September 2026.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong +10 more
wiley +1 more source
, 2018 Se evalúa la eficacia relativa de palbociclib-letrozol y ribociclib-letrozol en mujeres postmenopáusicas con cáncer de mama avanzado ER positivo HER2 negativo que no habían recibido terapia sistémica previa para la enfermedad avanzada a través de ...
Valle Corpas, Margarita +2 more
core
Cancer Medicine, Volume 15, Issue 9, September 2026.Cancer stem cell quiescence is a regulated, reversible survival mechanism, preserving stemness and promoting therapy resistance through intrinsic programs and niche signals. Targeting these pathways holds promise for eradicating quiescent CSCs and preventing recurrence.
Yasin Ahmadi +3 more
wiley +1 more source
Cancer Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background Cellular senescence influences cancer progression through irreversible cell‐cycle arrest, immune surveillance, and paracrine signaling mediated by the senescence‐associated secretory phenotype (SASP). SASP comprises inflammatory cytokines, chemokines, growth factors, and matrix‐remodeling enzymes that regulate the tumor ...
Sneha Pallatt +3 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala +5 more
wiley +1 more source
, 2018 Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Mara ...
Gostkorzewicz J +4 more
core
Breast Cancer Research, 2019 Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens.
Lorenzo Rossi +19 more
doaj +1 more source
Journal of Surgical Oncology, Volume 134, Issue 4, Page 490-501, September 15, 2026.ABSTRACT Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers.
Kristin E. Goodsell +5 more
wiley +1 more source
MedComm, Volume 7, Issue 9, September 2026.This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng +9 more
wiley +1 more source